Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. Our focus is on stimulating critical members of the immune response, known as CD4+ T helper cells. The technology allows for antigen-specific stimulation or suppression of a T-helper response to virtually any antigen of known pathogenic potential. Using this technology, Antigen Express is building a deep pipeline of therapeutics aimed at a variety of major diseases, including cancer, infectious diseases and autoimmune-based syndromes.

Antigen Express immunotherapies are based on highly selective modulation of the immune response through potent and antigen-specific stimulation of CD4+ T helper cells, resulting in highly effective agents with very low toxicity as compared with traditional cancer chemotherapy.  Advances in immunology, in particular those made by the founder of Antigen Express, Dr. Robert Humphreys, have demonstrated that it is possible to enlist the help of the immune system in combating diseases, including cancer.  The specificity inherent in a targeted immune response is unparalleled by traditionally designed small molecules.  The therapies developed at Antigen Express intervene at the critical stage of antigen presentation to modulate the immune response. This targeted approach results in a potent up or down regulation of vital members of the immune system.

The technologies developed at Antigen Express are novel and highly complementary to existing approaches of immune modification.  They have the added advantage of being ‘off-the-shelf’ products produced by entirely synthetic means.  Therefore, the company is uniquely positioned to both develop specific products as well as enter into partnerships where Antigen Express technology enhances the corporate partners’ strategic goals or product portfolio.

» return to top